{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T22:02:42Z","timestamp":1768687362634,"version":"3.49.0"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,12,1]]},"DOI":"10.2169\/internalmedicine.9423-22","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T22:11:05Z","timestamp":1651875065000},"page":"3617-3621","source":"Crossref","is-referenced-by-count":3,"title":["Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and Implications of New Biomarkers"],"prefix":"10.2169","volume":"61","author":[{"given":"Hajime","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohichi","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Emori","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotaka","family":"Hayasaka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Sugita","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91: 1914-1926, 2001.","DOI":"10.1002\/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 117: 1049-1054, 2011.","DOI":"10.1002\/cncr.25538"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Savina M, Le Cesne A, Blay JY, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med 15: 78, 2017.","DOI":"10.1186\/s12916-017-0831-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15: 415-423, 2014.","DOI":"10.1016\/S1470-2045(14)70063-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 18: 1397-1410, 2017.","DOI":"10.1016\/S1470-2045(17)30622-8"},{"key":"6","unstructured":"6. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42: 715-721, 2010."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379: 1879-1886, 2012.","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 16: 406-416, 2015.","DOI":"10.1016\/S1470-2045(15)70098-7"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Sch\u00f6ffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387: 1629-1637, 2016.","DOI":"10.1016\/S0140-6736(15)01283-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Huyck T, Gradishar W, Manuguid F, et al. Eribulin mesylate. Nat Rev Drug Discov 10: 173-174, 2011.","DOI":"10.1038\/nrd3389"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dottorini L, Catena L, Sarno I, Di Menna G, Marte A, Bajetta E. Long-lasting exceptional radiological complete response after treatment with eribulin in a patient with triple-negative breast cancer with liver involvement. Oncology 94: 6-9, 2018.","DOI":"10.1159\/000489062"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Goto Y, Yoshida T, Kimura M. Higher efficacy and complete response with administration of eribulin for recurrent squamous cell breast carcinoma: a case report. Mol Clin Oncol 9: 318-320, 2018.","DOI":"10.3892\/mco.2018.1676"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hayasaka N, Takada K, Nakamura H, et al. Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells. Sci Rep 9: 5759, 2019.","DOI":"10.1038\/s41598-019-42300-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tomita Y, Morooka T, Hoshida Y, et al. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12: 3070-3077, 2006.","DOI":"10.1158\/1078-0432.CCR-05-1732"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wozniak A, Boeckx B, Modave E, et al. Molecular biomarkers of response to eribulin in patients with leiomyosarcoma. Clin Cancer Res 27: 3106-3115, 2021.","DOI":"10.1158\/1078-0432.CCR-20-4315"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Du XH, Wei H, Zhang P, Yao WT, Cai QQ. Heterogeneity of soft tissue sarcomas and its implications in targeted therapy. Front Oncol 10: 564852, 2020.","DOI":"10.3389\/fonc.2020.564852"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/23\/61_9423-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:33:16Z","timestamp":1670038396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/23\/61_9423-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":16,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9423-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"article-number":"9423-22"}}